Sabyasachi Sen
Endocrinology, Diabetes & Metabolism · Washington, DCNPI 1215984968
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (42.1%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. Sanofi-aventis U.S. LLC accounts for 69.9% of it on its own, with 9 other manufacturers making up the rest.
Across 44 payments — averaging $270.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$8K
- Madrigal Pharmaceuticals$3K
- Novo Nordisk$430
- Bayer$232
- Kaneka Medical America LLC$165
- Boehringer Ingelheim$116
- plus $123 from 4 others
Across 23 payments — averaging $58,762 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk$658K
- Boehringer Ingelheim$414K
- AstraZeneca$146K
- Janssen Research & Development, LLC$134K
What the payments were for
- Consulting fees$5,00842%
- Speaking & faculty fees$3,87033%
- Food & beverage$3,00025%
- Education$180%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi-aventis U.S. LLC | 21 | $8,320 |
| Madrigal Pharmaceuticals | 5 | $2,508 |
| Novo Nordisk | 6 | $430 |
| Bayer | 4 | $232 |
| Kaneka Medical America LLC | 1 | $165 |
| Boehringer Ingelheim | 3 | $116 |
| AstraZeneca | 1 | $43 |
| Blueprint Medicines Corporation | 1 | $40 |
| Renalytix AI, Inc. | 1 | $22 |
| Merck | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DISEASE STATE$2,933
- REZDIFFRA$2,304
- TZIELD$710
- Kerendia$137
- SOLIQUA 100/33$123
How this compares
$11,896 in reported general payments places this provider in the 85th percentile of 44 endocrinology, diabetes & metabolism providers in District of Columbia.
See all endocrinology, diabetes & metabolism providers in District of Columbia →
Other endocrinology, diabetes & metabolism in Washington
- Natasa Janicic-KahricWashington$121K
- Diala El-MaoucheWashington$99K
- Abbas MotazediWashington$31K
- Meeta SharmaWashington$25K
- Joseph VerbalisWashington$24K
- Mark SklarWashington$14K
- Rui LuWashington$12K
- Qudsia HussainWashington$9K
- Jerold ShareWashington$7K
- Leonard WartofskyWashington$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.